<?xml version="1.0" encoding="UTF-8"?>
<p>MR was evaluated by 
 <italic>BCR-ABL1
  <sup>IS</sup>
 </italic> RQ-PCR analysis upon study entry and every 3 months thereafter in the consolidation phase. After discontinuing nilotinib in the TFR phase, molecular recurrence was monitored by monthly 
 <italic>BCR-ABL1
  <sup>IS</sup>
 </italic> RQ-PCR testing in the first year, bi-monthly testing in the second year, then every 3 months thereafter. In the re-treatment phase, 
 <italic>BCR-ABL1
  <sup>IS</sup>
 </italic> was monitored by monthly RQ-PCR testing. The study protocol was terminated when MR
 <sup>4.5</sup> was re-achieved, or when 
 <italic>BCR-ABL1
  <sup>IS</sup>
 </italic> increased twice consecutively in the re-treatment phase.
</p>
